Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Slagle Financial LLC

Slagle Financial LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,124 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the period. Slagle Financial LLC’s holdings in Gilead Sciences were worth $2,598,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. State Street Corp grew its position in Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares during the last quarter. Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter valued at approximately $1,789,254,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after acquiring an additional 249,804 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $111.16 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The firm has a market cap of $138.43 billion, a price-to-earnings ratio of 300.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company’s 50-day moving average is $105.08 and its two-hundred day moving average is $94.58. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences’s dividend payout ratio is 854.05%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Piper Sandler boosted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Bank of America boosted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.